» Articles » PMID: 30407583

FusionGDB: Fusion Gene Annotation DataBase

Overview
Specialty Biochemistry
Date 2018 Nov 9
PMID 30407583
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Gene fusion is one of the hallmarks of cancer genome via chromosomal rearrangement initiated by DNA double-strand breakage. To date, many fusion genes (FGs) have been established as important biomarkers and therapeutic targets in multiple cancer types. To better understand the function of FGs in cancer types and to promote the discovery of clinically relevant FGs, we built FusionGDB (Fusion Gene annotation DataBase) available at https://ccsm.uth.edu/FusionGDB. We collected 48 117 FGs across pan-cancer from three representative fusion gene resources: the improved database of chimeric transcripts and RNA-seq data (ChiTaRS 3.1), an integrative resource for cancer-associated transcript fusions (TumorFusions), and The Cancer Genome Atlas (TCGA) fusions by Gao et al. For these ∼48K FGs, we performed functional annotations including gene assessment across pan-cancer fusion genes, open reading frame (ORF) assignment, and retention search of 39 protein features based on gene structures of multiple isoforms with different breakpoints. We also provided the fusion transcript and amino acid sequences according to multiple breakpoints and transcript isoforms. Our analyses identified 331, 303 and 667 in-frame FGs with retaining kinase, DNA-binding, and epigenetic factor domains, respectively, as well as 976 FGs lost protein-protein interaction. FusionGDB provides six categories of annotations: FusionGeneSummary, FusionProtFeature, FusionGeneSequence, FusionGenePPI, RelatedDrug and RelatedDisease.

Citing Articles

A New Approach of Detecting Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis.

Zakharova G, Suntsova M, Rabushko E, Mohammad T, Drobyshev A, Seryakov A Cancers (Basel). 2024; 16(22).

PMID: 39594806 PMC: 11592821. DOI: 10.3390/cancers16223851.


Evaluation of whole genome sequencing utility in identifying driver alterations in cancer genome.

Nagashima T, Yamaguchi K, Urakami K, Shimoda Y, Ohnami S, Ohshima K Sci Rep. 2024; 14(1):23898.

PMID: 39396060 PMC: 11470963. DOI: 10.1038/s41598-024-74272-0.


Artificial intelligence in fusion protein three-dimensional structure prediction: Review and perspective.

Kumar H, Kim P Clin Transl Med. 2024; 14(8):e1789.

PMID: 39090739 PMC: 11294035. DOI: 10.1002/ctm2.1789.


Cancer fusion transcripts with human non-coding RNAs.

Mohammad T, Zolotovskaia M, Suntsova M, Buzdin A Front Oncol. 2024; 14:1415801.

PMID: 38919532 PMC: 11196610. DOI: 10.3389/fonc.2024.1415801.


Pathway-based, reaction-specific annotation of disease variants for elucidation of molecular phenotypes.

Orlic-Milacic M, Rothfels K, Matthews L, Wright A, Jassal B, Shamovsky V Database (Oxford). 2024; 2024.

PMID: 38713862 PMC: 11184451. DOI: 10.1093/database/baae031.


References
1.
Souttou B, Carvalho N, Raulais D, Vigny M . Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem. 2000; 276(12):9526-31. DOI: 10.1074/jbc.M007333200. View

2.
Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zahler A . The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006. PMC: 186604. DOI: 10.1101/gr.229102. View

3.
Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

4.
Slany R . Chromatin control of gene expression: mixed-lineage leukemia methyltransferase SETs the stage for transcription. Proc Natl Acad Sci U S A. 2005; 102(41):14481-2. PMC: 1253606. DOI: 10.1073/pnas.0507401102. View

5.
Higgins M, Claremont M, Major J, Sander C, Lash A . CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res. 2006; 35(Database issue):D721-6. PMC: 1781153. DOI: 10.1093/nar/gkl811. View